Immunocore doses first patient in Phase 1 trial of IMC-S118AI for type 1 diabetes

• Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first autoimmune disease candidate, for type 1 diabetes.
• The dose-escalation study will evaluate safety, pharmacokinetics and clinical activity in patients with a specific genetic marker.
• The tissue-targeted therapy is designed to protect insulin-producing beta cells by suppressing autoreactive T cells.
• Preclinical results already published in Science Advances showed reduced autoreactive T-cell activity in human pancreatic tissue, helping preserve beta cells and insulin secretion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150700PRIMZONEFULLFEED1001278094) on October 15, 2026, and is solely responsible for the information contained therein.